Gut · 2026-07-16
Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality
Phrase rank #1 · DOI 10.1136/gutjnl-2026-339142
Conditions & diseases
steatotic liver disease
Observed in 82 articles across 19 journals.
Latest share0.26%
Change vs baseline-0.09 pp
Months observed12
Latest monthJul 2026
Portfolio article share
Attention over this snapshot
13 monthly points
Journal breadth
Where it appears
- Gut43
- Frontline Gastroenterology7
- BMJ Open6
- eGastroenterology5
- BMJ Open Gastroenterology4
- BMJ Open Diabetes Research & Care3
- BMJ Medicine2
- BMJ1
- BMJ Evidence-Based Medicine1
- BMJ Health & Care Informatics1
- BMJ Immunology1
- BMJ Nutrition, Prevention & Health1
Co-occurrence
Explore nearby topics
Inspect the source signal
Article evidence
30 high-ranking examples
Gut · 2026-07-01
CTCF-rs705704-SUOX axis is important for the association between hypothyroidism and metabolic dysfunction-associated steatotic liver disease
Phrase rank #1 · DOI 10.1136/gutjnl-2026-339457
Gut · 2026-06-26
IDDF2026-ABS-0303 Cardiovascular-kidney-metabolic syndrome and the risk of liver-related and cardiovascular events across the steatotic liver disease spectrum
Phrase rank #1 · DOI 10.1136/gutjnl-2026-IDDF.199
Gut · 2026-06-26
IDDF2026-ABS-0233 Multi-target mechanisms of morus ALBA leaf bioactives in metabolic dysfunction-associated steatotic liver disease: a network pharmacology study
Phrase rank #1 · DOI 10.1136/gutjnl-2026-IDDF.108
Gut · 2026-06-26
IDDF2026-ABS-0156 Does measuring the components of the fibrosis-4 index (FIB-4) separately on different days affect its performance in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)?
Phrase rank #1 · DOI 10.1136/gutjnl-2026-IDDF.184
Gut · 2026-06-26
IDDF2026-ABS-0453 Artificial intelligence (AI) driven early detection of metabolic dysfunction associated steatotic liver disease (MASLD) in primary care
Phrase rank #1 · DOI 10.1136/gutjnl-2026-IDDF.221
Gut · 2026-06-26
IDDF2026-ABS-0364 Steatotic liver disease subtypes exhibit distinct risk patterns of tachyarrhythmias and bradyarrhythmias
Phrase rank #1 · DOI 10.1136/gutjnl-2026-IDDF.206
BMJ Open · 2026-06-25
Body weight categories and fat distribution in relation to all-cause mortality among adults with metabolic dysfunction-associated steatotic liver disease: a population-based analysis of NHANES, 2007–2018
Phrase rank #1 · DOI 10.1136/bmjopen-2025-113719
Gut · 2026-06-23
P97 Metabolic dysfunction-associated steatotic liver disease in the United Kingdom: latest insights into disease incidence and burden
Phrase rank #1 · DOI 10.1136/gutjnl-2026-BSG.232
Gut · 2026-06-23
P53 Inefficient surveillance of low-risk steatotic liver disease: a call for resource reallocation
Phrase rank #1 · DOI 10.1136/gutjnl-2026-BSG.189
BMJ Open · 2026-06-22
Diagnostic performance of neck circumference for detecting steatotic liver disease in adults: a systematic review and meta-analysis protocol
Phrase rank #1 · DOI 10.1136/bmjopen-2026-117491
BMJ Open Diabetes Research & Care · 2026-06-03
Reduced circulating Mig-6 levels are associated with dysglycemia in metabolic dysfunction associated steatotic liver disease (MASLD)
Phrase rank #1 · DOI 10.1136/bmjdrc-2026-005947
eGastroenterology · 2026-05-22
From static labels to dynamic trajectories: MASLD–MetALD–ALD as a dynamic continuum within the framework of steatotic liver disease
Phrase rank #1 · DOI 10.1136/egastro-2026-100430
BMJ Open Gastroenterology · 2026-05-05
Using the enhanced liver fibrosis test to identify disease in at-risk populations
Phrase rank #1 · DOI 10.1136/bmjgast-2025-002048
BMJ Medicine · 2026-04-27
Correction: Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults
Phrase rank #1 · DOI 10.1136/bmjmed-2025-002038corr1
Gut · 2026-04-21
Letter to the editor regarding: Lai, Jimmy Che-To, et al "Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease"
Phrase rank #1 · DOI 10.1136/gutjnl-2026-339053
BMJ Open · 2026-04-08
Safety and efficacy of pharmacological interventions for hepatic outcomes of metabolic dysfunction-associated steatotic liver disease: protocol for systematic review and network meta-analysis
Phrase rank #1 · DOI 10.1136/bmjopen-2025-111933
Frontline Gastroenterology · 2026-04-07
Metabolic-associated steatotic liver disease (MASLD): how I evolved my approach to diagnosis and staging
Phrase rank #1 · DOI 10.1136/flgastro-2024-102705
BMJ Medicine · 2026-03-31
Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults
Phrase rank #1 · DOI 10.1136/bmjmed-2025-002038
BMJ Open · 2026-01-28
Development of a machine learning-based model for prediction of diabetes risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
Phrase rank #1 · DOI 10.1136/bmjopen-2025-107239
Gut · 2026-01-21
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement
Phrase rank #1 · DOI 10.1136/gutjnl-2025-337374
Gut · 2026-01-20
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease
Phrase rank #1 · DOI 10.1136/gutjnl-2025-337275
BMJ Health & Care Informatics · 2025-12-12
Developing a non-invasive algorithm for the diagnosis of steatotic liver disease in primary healthcare: a retrospective cohort study
Phrase rank #1 · DOI 10.1136/bmjhci-2025-101620
BMJ · 2025-11-13
Diagnosis and management of metabolic dysfunction associated steatotic liver disease
Phrase rank #1 · DOI 10.1136/bmj-2025-084950
Gut · 2025-10-06
P11 Dietary patterns, physical activity levels and mental health status of patients with metabolic dysfunction-associated steatotic liver disease living in East London
Phrase rank #1 · DOI 10.1136/gutjnl-2025-BASL.28
Gut · 2025-10-06
P90 Effectiveness of a multidisciplinary hepatology-diabetes clinic in managing patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus
Phrase rank #1 · DOI 10.1136/gutjnl-2025-BASL.105
Gut · 2025-10-06
P24 Non-invasive fibrosis assessment in metabolic dysfunction-associated steatotic liver disease – redefining the grey zone
Phrase rank #1 · DOI 10.1136/gutjnl-2025-BASL.40
eGastroenterology · 2025-09-12
Steatotic liver disease and cancer: from pathogenesis to therapeutic targets
Phrase rank #1 · DOI 10.1136/egastro-2025-100218
BMJ Open Gastroenterology · 2026-07-02
Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics
Phrase rank #2 · DOI 10.1136/bmjgast-2026-002343
Gut · 2026-06-26
IDDF2026-ABS-0413 C-reactive protein-triglyceride-glucose index, 25-hydroxyvitamin D, and mortality risk in metabolic dysfunction-associated steatotic liver disease
Phrase rank #2 · DOI 10.1136/gutjnl-2026-IDDF.211